OPPM
CRSP icon

Opus Point Partners Management’s CRISPR Therapeutics CRSP Stock Holding History

Opus Point Partners Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$542K Hold
13,214
– – 0.98% 24
2019
Q2 		$622K Hold
13,214
– – 0.92% 30
2019
Q1 		$472K Buy
+13,214
New +$457K 0.64% 38

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Opus Point Partners Management's CRSP Position: Q3 2019 in Review

Opus Point Partners Management held its CRISPR Therapeutics (CRSP) position steady in Q3 2019 at 13,214 shares worth $542K. The position accounts for 0.98% of the portfolio, ranked #24.

Opus Point Partners Management first reported a position in CRSP in Q1 2019 and has held it in 3 quarters since. The position peaked at $622K in Q2 2019. 182 funds tracked by Wall St. Rank hold CRSP as of Q3 2019.

  • Opus Point Partners Management held 13,214 shares of CRISPR Therapeutics worth $542K as of Q3 2019.
  • Opus Point Partners Management left its CRISPR Therapeutics share count unchanged in Q3 2019.
  • CRISPR Therapeutics made up 0.98% of Opus Point Partners Management's portfolio in Q3 2019, its #24 holding.
  • Opus Point Partners Management first reported a position in CRISPR Therapeutics in Q1 2019 and has held it in 3 quarters since.
  • Opus Point Partners Management's CRISPR Therapeutics position peaked at $622K in Q2 2019.
  • 182 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.